Who
Heidi Henson
Director
Company insider
Files Form 4 as: Director, PepGen; Director, Perspective Therapeutics; Director, Lisata Therapeutics; Chief Financial Officer, Pardes Biosciences; Chief Financial Officer, Kura Oncology.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 0
- Bought
- $100K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 11 Nov 2015
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,789 at $0.00 | filing |
| 4 Dec 2024filed 6 Dec 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K25,975 at $3.85 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 9 Jan 2024filed 11 Jan 2024 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —19,480 at $0.00 | filing |
| 12 Dec 2023filed 14 Dec 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Pardes Biosciencesoption or derivative | SEC FORM 4 Code D | —156,250 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Pardes Biosciencesoption or derivative | SEC FORM 4 Code D | —241,593 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Pardes Biosciencesoption or derivative | SEC FORM 4 Code D | —160,000 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Pardes Biosciencesoption or derivative | SEC FORM 4 Code D | —125,000 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Pardes Biosciences | SEC FORM 4 Code U | —316,753 | filing |
| 22 Jun 2023filed 26 Jun 2023 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
FDA Grants Fast Track To Perspective Therapeutics' PSV359CATX · finanzen.ch · 8 Oct 2026Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumCATX · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Heidi Henson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.